Table 2.
Medical treatments, procedural findings, and in-hospital outcomes
| Characteristic | Total (n = 4,874) | All population (n = 4,874) |
Cardiogenic shock (n = 282) |
||||
|---|---|---|---|---|---|---|---|
| STDT ≤ 60 min (n = 1,386) | STDT > 60 min (n = 3,488) | p value | STDT ≤ 60 min (n = 130) | STDT > 60 min (n = 152) | p value | ||
| Aspirin | 4,861 (99.7) | 1,379 (99.5) | 3,482 (99.8) | 0.084 | 124 (95.4) | 149 (98.0) | 0.358 |
| Clopidogrel | 3,074 (63.1) | 834 (60.2) | 2,240 (64.2) | 0.009 | 70 (53.8) | 85 (55.9) | 0.819 |
| Ticagrelor | 1,043 (21.4) | 325 (23.4) | 718 (20.6) | 0.031 | 25 (19.2) | 25 (16.4) | 0.650 |
| Prasugrel | 607 (12.5) | 182 (13.1) | 425 (12.2) | 0.393 | 15 (11.5) | 10 (6.6) | 0.211 |
| Beta-blockers | 4,155 (85.2) | 1,197 (86.4) | 2,958 (84.8) | 0.180 | 82 (63.1) | 73 (48.0) | 0.016 |
| ACE inhibitors | 2,571 (52.7) | 733 (52.9) | 1,838 (52.7) | 0.929 | 52 (40.0) | 45 (29.6) | 0.088 |
| ARBs | 1,305 (26.8) | 348 (25.1) | 957 (27.4) | 0.105 | 23 (17.7) | 26 (17.1) | 1.000 |
| Statins | 4,464 (91.6) | 1,272 (91.8) | 3,192 (91.5) | 0.811 | 86 (66.2) | 89 (58.6) | 0.235 |
| GP IIb/IIIa inhibitor | 1,076 (22.1) | 309 (22.3) | 767 (22.0) | 0.847 | 42 (32.3) | 44 (28.9) | 0.630 |
| Multi-vessel diseasedz. | 2,265 (46.5) | 638 (46.0) | 1,627 (46.6) | 0.722 | 76 (58.5) | 95 (62.5) | 0.569 |
| LAD related diseasedz. | 2,456 (50.4) | 713 (51.4) | 1,743 (50.0) | 0.371 | 40 (30.8) | 55 (36.2) | 0.405 |
| Lesion type B1/B2 | 2,224 (45.6) | 612 (44.2) | 1,612 (46.2) | 0.204 | 58 (44.6) | 62 (40.8) | 0.598 |
| Lesion type C | 2,609 (53.5) | 754 (54.4) | 1,855 (53.2) | 0.461 | 69 (53.1) | 89 (58.6) | 0.422 |
| Thrombus aspiration | 1,854 (38.0) | 515 (37.2) | 1,339 (38.4) | 0.444 | 41 (31.5) | 56 (36.8) | 0.419 |
| Using BMS | 131 (2.7) | 38 (2.7) | 93 (2.7) | 0.961 | 9 (6.9) | 11 (7.2) | 1.000 |
| IABP | 242 (5.0) | 71 (5.1) | 171 (4.9) | 0.806 | 27 (20.8) | 47 (30.9) | 0.073 |
| ECMO | 75 (1.5) | 27 (1.9) | 48 (1.4) | 0.182 | 18 (13.8) | 19 (12.5) | 0.875 |
| Complete revascularisationa | 4,809 (98.7) | 1,369 (98.8) | 3,440 (98.6) | 0.568 | 123 (94.6) | 144 (94.7) | 0.748 |
| Hospital death | 207 (4.2) | 58 (4.2) | 149 (4.3) | 0.954 | 33 (25.4) | 60 (39.5) | 0.017 |
| Cardiac death | 187 (3.8) | 54 (3.9) | 133 (3.8) | 0.957 | 32 (24.6) | 55 (36.2) | 0.049 |
| Non-cardiac death | 20 (0.4) | 4 (0.3) | 16 (0.5) | 0.555 | 1 (0.8) | 5 (3.3) | 0.295 |
| Newly developed HF | 172 (3.5) | 47 (3.4) | 125 (3.6) | 0.808 | 9 (6.9) | 21 (13.8) | 0.093 |
| VT/VF | 395 (8.1) | 134 (9.7) | 261 (7.5) | 0.014 | 41 (31.5) | 54 (35.5) | 0.562 |
| TIMI major bleeding | 100 (2.1) | 30 (2.2) | 70 (2.0) | 0.812 | 15 (11.5) | 14 (9.2) | 0.656 |
| TIMI minor bleeding | 150 (3.1) | 38 (2.7) | 112 (3.2) | 0.445 | 9 (6.9) | 10 (6.6) | 1.000 |
Values are presented as number (%).
STDT, symptom-to-door time; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; GP, glycoprotein; dz, disease; LAD, left anterior descending artery; BMS, bare metal stent; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane oxygenation; HF, heart failure; VT/VF, ventricular tachycardia/ventricular fibrillation; TIMI, thrombolysis in myocardial infarction.
a
Angiographic complete revascularisation was defined as minimum stenosis diameter reduction to less than 20%.